Compare Crocs, Inc. (CROX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs Sana Biotechnology Inc — how do they compare? Crocs, Inc. trades at $131.73 (market cap $6.31B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Crocs, Inc. is far larger — about 5.6× Sana Biotechnology Inc's market cap, and Crocs, Inc. is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| CROX | SANA | |
|---|---|---|
Market Cap | $6.31B | $1.13B |
Sector | Consumer Staples | Health |
52-Week High | $141.19 | $5.92 |
52-Week Low | $73.39 | $2.68 |
Enterprise Value | $7.83B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $130.55, down 5.53% amid negative sentiment from recent tax haven scrutiny and a weak Q3 outlook. The stock shows strong fundamentals with three consecutive earnings beats and attractive valuation metrics (P/E 11.69, P/S 1.67). Technical indicators are mixed with bearish signals but key support at $128. Revenue remains stable at $4B+ with robust gross margins of 57.47%.
Despite near-term headwinds, CROX offers value with analyst consensus target of $140.43 (7.6% upside). Risks include tax regulation scrutiny, HEYDUDE brand weakness, and tariff pressures. The company maintains strong profitability metrics (ROE 42.3%) and raised full-year 2026 guidance, supporting long-term growth potential.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
